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Background. Relative little attention has been devoted until now to the combined effects of gene polymorphisms of the
hemostatic pathway as risk factors for Myocardial Infarction (MI), the main thrombotic complication of Coronary Artery Disease
(CAD). The aim of this study was to evaluate the combined effect of ten common prothrombotic polymorphisms as a
determinant of MI. Methodology/Principal Findings. We studied a total of 804 subjects, 489 of whom with angiographically
proven severe CAD, with or without MI (n=307; n=182; respectively). An additive model considering ten common
polymorphisms [Prothrombin 20210G.A, PAI-1 4G/5G, Fibrinogen b -455G.A, FV Leiden and ‘‘R2’’, FVII -402G.A and -323 del/
ins, Platelet ADP Receptor P2Y12 -744T.C, Platelet Glycoproteins Ia (873G.A), and IIIa (1565T.C)] was tested. The prevalence
of MI increased linearly with an increasing number of unfavorable alleles (x
2 for trend=10.68; P=0.001). In a multiple logistic
regression model, the number of unfavorable alleles remained significantly associated with MI after adjustment for classical
risk factors. As compared to subjects with 3-7 alleles, those with few (#2) alleles had a decreased MI risk (OR 0.34, 95%CIs 0.13–
0.93), while those with more ($8) alleles had an increased MI risk (OR 2.49, 95%CIs 1.03–6.01). The number of procoagulant
alleles correlated directly (r=0.49, P=0.006) with endogenous thrombin potential. Conclusions. The combination of
prothrombotic polymorphisms may help to predict MI in patients with advanced CAD.
Citation: Martinelli N, Trabetti E, Pinotti M, Olivieri O, Sandri M, et al (2008) Combined Effect of Hemostatic Gene Polymorphisms and the Risk of
Myocardial Infarction in Patients with Advanced Coronary Atherosclerosis. PLoS ONE 3(2): e1523. doi:10.1371/journal.pone.0001523
INTRODUCTION
Myocardial Infarction (MI), the leading complication of coronary
atherosclerotic disease (CAD), generally occurs in the late stages of
disease because of coronary thrombosis superimposed on a
ruptured/unstable plaque [1]. In clinical practice it is well-known
that, in spite of the documented presence of advanced CAD, only
a subset of patients develops acute MI during their life-course [2].
The reasons for individual differences in susceptibility to MI are
poorly understood. In principle, subjects with an increased
tendency to form blood clots (i.e. with ‘‘hypercoagulability’’) may
be at increased risk, as observed for venous thrombosis. Lessons
from animal models suggest that excessive thrombin generation
may be particularly harmful during the later stages of atheroscle-
rosis, when thrombotic complications often occur [3,4]. However,
this is difficult to assess in clinical practice, since we lack a unique
and reliable laboratory marker of hypercoagulability [5]. More-
over, functional tests evaluating concentration and/or function of
blood coagulation proteins are often subjected to multiple
transient interferences, e.g. due to the use of antithrombotic and
anticoagulant agents or the presence of concomitant inflamma-
tion. Genetic polymorphisms with a documented functional effect
on blood coagulation proteins may represent a useful tool, by
reflecting the individual’s lifelong exposure to even a mild
prothrombotic state. During the last decade, extensive studies on
various individual polymorphisms as risk factors for CAD and MI
have yielded largely inconclusive results [6–11]. These results
reflect at least two critical issues: 1) the multifactorial and multistep
pathogenesis of CAD, involving many different biochemical
pathways and intermediate phenotypes (e.g. hyperlipidemia,
diabetes, hypertension), each in turn under the control of many
different genes; 2) the enormous heterogeneity of investigations in
terms of study design, typology of patients included, and clinical
endpoints [10]. There has also been relatively little attention
devoted to assess the combined effect of genes, which might be
anticipated by analogy to the well-known additive effects of
conventional risk factors. Generally, individual polymorphisms
confer a marginal to moderate CAD risk that becomes evident only
across many thousands of individuals, as was recently demonstrated
by meta-analysis for Factor V 1691 G.A (Factor V Leiden),
prothrombin 20210 G.A,andPAI-1 -6754G/5G [8]. Thisrenders
suchpolymorphismsunhelpfulinassessing individuals’riskclinically.
On the other hand, the value of analyzing multiple alleles
simultaneously for determining the risk is not well studied.
In this study we evaluated the combined effect of ten common
genetic variants, with known modest effects on the hemostatic
balance (listed in Table 1) [6,12–21], in modulating the risk of
development of MI. Because of the relatively late occurrence of MI
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PLoS ONE | www.plosone.org 1 February 2008 | Issue 2 | e1523in the natural history of CAD, we focused on a selected population
of high risk patients with angiographically documented, advanced
CAD. A thrombin generation assay was also used in a subset of
patients to explore the propensity to form blood clot as a function
of the number of hemostatic polymorphisms.
RESULTS
Haemostatic polymorphisms in the CAD group as a
whole versus CAD-free subjects
Supplemental Table 1 (TableS1) showsthe genotype frequenciesfor
each of the 10 polymorphisms in CAD-free (n=315; males 66.0%;
mean age 59.2611.9 years) and in CAD subjects (n=489; males
83.6%; mean age 60.369.3 years). All alleles were in Hardy-
Weinberg equilibrium. For each polymorphism there was no
significant difference in genotype distribution between CAD and
CAD-free groups. The distribution of the ‘‘prothrombotic score’’
(PS) in the whole study population (n=804) is shown in figure 1A.
The score ranged from 0 (1 subject) to 10 prothrombotic alleles (7
subjects), with a median level of 5. Figure 1B shows the distribution
of the PS in CAD-free and in CAD subjects. No association was
found between the PS and CAD (P=0.889 by x
2-test).
Individual haemostatic polymorphisms and MI risk
in subjects with advanced CAD
Supplemental Table 2 (Table S2) shows the general characteristics
of the CAD population divided in two groups on the basis of
presence/absence of MI. As compared to CAD patients without
MI, MI patients were significantly younger, more frequently
males, had a higher degree of CAD in terms of number of diseased
vessels, and lower HDL-cholesterol levels. No significant difference
was found for the other variables. Table 2 shows the genotype
frequencies of the 10 genetic variants in CAD patients with or
without MI. Two polymorphisms, factor VII -402 G.A and
fibrinogen b-chain -455 G.A, showed nominal association with
MI at the univariate analysis. However, these associations were no
longer significant after multiple logistic regression adjusted for sex,
age, disease severity, smoking status, BMI, LDL- and HDL-
cholesterol (P=0.155 for factor VII -402 G/A and P=0.998 for
fibrinogen b-chain -455 G/A).
Combined effect of haemostatic polymorphisms and
MI risk
No significant interaction was found by CART among polymor-
phisms in determining MI risk (all P for interaction .0.05). As
shown in figure 1C, the proportion of CAD patients with MI
increased progressively with increasing number of unfavourable
alleles (x
2 for linear trend=10.68; P=0.001). In a multiple logistic
regression model the prothrombotic score remained significantly
associated with MI after adjustment for sex, age, degree of CAD,
smoke, BMI, LDL- and HDL-cholesterol (OR for 1-point increase
in prothrombotic score=1.22 with 95%CI 1.06–1.39, P=0.004).
Using the median of PS as cut-off, CAD patients with .5 alleles
had a significantly increased risk of MI as compared to subjects
with #5 alleles (OR 2.02 with 95%CI 1.27–3.21, P=0.003, by
multiple logistic regression). Using approximately the 5
th and the
95
th percentiles of PS distribution (i.e. 2 and 8, respectively), the
study population could be classified into in 3 subgroups: a low-risk
group with less than 3 unfavourable alleles (n=26), an
intermediate-risk group with 3 to 7 unfavourable alleles
(n=417), and a high-risk group with more than 7 unfavourable
alleles (n=46). The prevalence of MI among these groups
increased progressively (38.5% in low-risk; 62.6% in intermedi-
ate-risk; and 78.3% in high-risk; P=0.001 by x
2 for linear trend),
while they were similar for the other clinical and laboratory
variables (data not shown). Considering the intermediate-risk
group as the reference group, carriers of ,3 alleles had a lower
risk of MI, while carriers of .7 alleles had an increased risk
(Figure 2). Comparing the two extreme groups, the subjects with
.7 alleles had a remarkably higher MI risk (OR 7.28 with 95%CI
2.01–26.36, P=0.002 adjusted by multiple logistic regression).
The ROC curve for information provided by our polygenic
approach for MI prediction in CAD patients is plotted in
Supplemental Figure 1 (Figure S1). The AUC was 0.581 with a
95% CI from 0.530 to 0.632.
Combined effect of haemostatic polymorphisms and
thrombin generation activity
To get insights on the pathophysiological effect of combined
hemostatic alleles, we assessed the characteristics of thrombin
Table 1. Description of the haemostatic gene polymorphisms, analysed in this study, and their associated intermediate phenotype.
..................................................................................................................................................
Polymorphism
Chromosome
location of gene Effects on intermediate phenotype
FIBRINOGEN beta-chain –455 G.A [fibrinogen] 4q28 -455 AA genotype associated with fibrinogen concentrations that are 10%
higher than GG genotype
12
Factor VII A1/A2 [coagulation factor VII] 13q34 A2 associated with reduced factor VII concentrations
13
Factor VII–402 G.A [coagulation factor VII] 13q34 -402A associated with increased factor VII concentrations
14
Factor V Leiden (R506Q) [coagulation factor V] 1q23 506Q is a cause of activated protein C (APC) resistance
15
Factor V R2 (6755 A.G) [coagulation factor V] 1q23 6755G associated with mild APC-resistance and impaired APC mediated
factor VIII inactivation
16
PROTHROMBIN 20210 G.A [precursor of thrombin] 11p11-q12 20210A associated with increased plasma prothrombin levels
17
PAI-1–675 5G/4G [inhibitor of plasminogen activator] 7q21.3-q22.1 4G associated with increased plasma PAI-1 Levels
18
GP IIIa Leu33Pro [platelet receptor for fibrinogen and von
Willebrand factor]
17q21.32 33Pro might increase sensitivity to platelet aggregation
19
GP Ia/IIa alfa2 873 G.A [platelet receptor for collagen] 5q23-q31 873A (in linkage with 807T polymorphism) might increase the receptor
density
20
P2RY12 H1/H2 (-744T.C) [platelet receptor for ADP] 3q24-q25 -744C, in absolute linkage disequilibrium with 3 others SNPs, marks the H2
haplotype, that is associated with maximal aggregation response to ADP
21
doi:10.1371/journal.pone.0001523.t001
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PLoS ONE | www.plosone.org 2 February 2008 | Issue 2 | e1523generation activity curves as a function of the number of
procoagulant alleles (i.e. fibrinogen b-chain -455 A, Prothrombin
20210 A, Factor V Leiden, Factor V R2, Factor VII A1, Factor
VII -402 A and PAI-1 -675 4G). Since this assay pertains only to
the coagulation pathway, the three platelet-related polymorphisms
were not considered for this analysis. This assay was performed in
a subset of 29 CAD patients (26 males and 3 females, 22 with and
7 without MI), selected among those without possible confounders
(i.e. concomitant anticoagulant therapy or overt signs of
inflammation, documented by hs-CRP,5 mg/l), in order to form
three groups matched for age and sex representing the previously
defined risk groups (low-risk: n=9, 8 males and 1 female, mean
age 53.768.5; intermediate-risk: n=10, 9 males and 1 female,
mean age 57.867.4; high-risk: n=10, 9 males and 1 female, mean
age 56.068.6). The number of procoagulant alleles was signifi-
cantly associated with ETP and with Start Tail, but not with Lag
Time, Peak or Time to Peak (Table 3). Similarly, subjects with a
high number of procoagulant alleles ($5) had significantly higher
ETP values as compared to subjects with fewer alleles (Table 4).
These two groups were similar not only for age and sex, but also
for smoking, hypertension and diabetes (data not shown). Their
median thrombin generation activity curves are showed in
Figure 3.
DISCUSSION
Evidence that a hypercoagulable state is associated with increased
mortality has been provided by some recent studies [11,22]. To
our knowledge, this is the first study that attempts to look at the
impact of the combined effect of several common prothrombotic
polymorphisms in the identification of CAD patients at different
risk of developing MI. To put our results into perspective, we
propose the following considerations.
Single haemostatic polymorphisms and MI risk
This study focused on relatively few genetic variants associated
with defined biochemical alterations. While some of them (i.e.
Factor V Leiden and prothrombin 20210 G.A) are established
risk factors for venous thromboembolism, their association with
arterial thrombosis is much less convincing [6,9]. Here too, despite
some nominal significant P values, we found no consistent
association when each polymorphism was considered individually.
Figure 1. Study population (n=804) stratified on the basis of number of risk alleles (1A). The distribution of number of risk alleles in CAD-free
(n=315) and in CAD patients (n=489) (1B) and in CAD patients with (n=307) or without a history of MI (n=182) (1C).
doi:10.1371/journal.pone.0001523.g001
Hemostatic Genes and MI Risk
PLoS ONE | www.plosone.org 3 February 2008 | Issue 2 | e1523Indeed, CAD and MI are paradigms of complex disease, in which
the effect of individual genes on the risk is anticipated to be weak
[23,24]. Moreover, emphasizing the principle that ‘‘the highest the
allele effect, the lowest the allele frequency’’ [25], it is plausible
that genetic variants such those investigated in the present study,
relatively frequent in the general population, could have at best
only a mild effect on a potentially lethal phenotype like MI.
Indeed, until now only a recent large meta-analysis including tens
of thousands of patients has been able to detect a moderate but
significant increase in the risk of coronary disease associated with
either the Factor V Leiden mutation or the prothrombin 20210A
variant [8].
Combined effect of haemostatic polymorphisms and
MI risk
Recently, a polygenic approach has been demonstrated to be a valid
tool to identify subjects at risk for another complex trait such as type
2 diabetes [26]. A similar strategy was used in the present study,
suggesting that in subjects with advanced CAD, an increasing
number of prothrombotic alleles may confer a significant risk of
developing MI. It is biologically plausible that the simultaneous
presence of several genetic variations with modest but defined effects
on the hemostatic process could influence the risk of the major
thrombotic complication in a given CAD patient. Under certain
stimuli, such as plaque erosion or rupture, this condition may
predispose to sustained thrombin generation leading to the acute
thrombotic event [2]. Accordingly, our in vitro functional studies
showed an association between the number of procoagulant alleles
and thrombin generation. The latter is known to be a highly variable
and complex phenomenon modulated by the interplay of several
factors, none of them with predominant influence, many of them
under genetic control [27]. It is noteworthy that our clinical model
focused on a homogeneous group of patients with angiographically
proven advanced CAD. Elegant studies in animal models, i.e. Factor
V Leiden mice crossbred with apolipoprotein E–deficient mice,
indicates that unregulated thrombin generation is particularly
harmful during the later stages of atherosclerosis. [3,4]. Conversely,
a mild hypercoagulable state may be less meaningful in absence of
underlying vulnerable atherosclerotic plaques. Our results may thus
apply only to the specific clinical model of this study, and not to all
CAD patients. While it is reasonable that genetically-induced
excessive thrombin generation may be clinically relevant in subjects
with extensive coronary plaques, this excess might be less influential
in the atherogenetic process, where other genetic factors (i.e. those
involved in modulation of lipid metabolism, antioxidant balance,
and so on) may be prominent. This could explain why we found no
association between the hemostatic polymorphisms and the CAD
phenotype.
Study limitations and strengths
One strength of our study is the clear definition of phenotypes,
allowing comparison of patients with angiographically proven,
advanced CAD, with or without MI. The CAD population had a
substantial burden of traditional risk factors and thus represented a
typical patient population seen in clinical practice.
Our study has several limitations, including the relatively low
number of subjects and polymorphisms and a retrospective case-
controldesign.Inthissettingthepossibleconfoundingofthesurvivor
effect should also be taken into account. The prothrombotic score,
calculated as the sum of prothrombotic alleles, is likely an
oversimplification, since it standardized the contribution of each
gene variant and does not allow distinguishing the possible different
transmission models, as well as the different biological weight of the
polymorphisms. Nevertheless, for complex traits the presence of
additive effects of many genes is considered more likely than
interactive effects [28,29], and additive models have been shown to
perform well, even when the underlying model is unknown [30,31].
This study can be viewed as hypothesis-generating, shedding
light into the potential usefulness of a polygenic approach in
appropriate clinical contexts. Indeed, the predictive power of our
additive genetic model was relatively low, yielding an area under
Table 2. Genotypes frequencies (%) of the CAD population,
with or without MI.
......................................................................
No MI (n=182) MI (n=307) P *
FIBRINOGEN beta-chain –455 G.A
GG 65.4 59.9 0.028
GA 34.1 35.2
AA 0.5 4.9
Factor VII A1/A2
A1A1 63.7 70.4 0.240
A1A2 31.3 26.7
A2A2 5.0 2.9
Factor VII–402 G.A
GG 73.1 61.2 0.016
GA 23.1 35.5
AA 3.8 3.3
Factor V Leiden (R506Q)
RR 96.7 96.8 0.725
RQ 3.3 2.9
QQ 00 . 3
Factor V R2 (6755 A.G)
AA 83.5 82.1 0.917
AG 15.4 16.6
GG 1.1 1.3
Prothrombin 20210 G.A
GG 96.7 94.1 0.204
GA 3.3 5.9
AA 00
PAI-1–675 5G/4G
4G-4G 29.2 30.0 0.951
4G-5G 51.6 50.1
5G-5G 19.2 19.9
GP IIIa Leu33Pro
Leu/Leu 75.8 69.7 0.210
Leu/Pro 23.7 28.3
Pro/Pro 0.5 2.0
GP Ia/IIa alfa2 873 G.A
GG 41.2 37.8 0.740
GA 46.2 48.2
AA 12.6 14.0
P2RY12 H1/H2 (-744T.C)
TT 77.5 73.6 0.234
TC 22.5 25.1
CC 01 . 3
*:b yx
2-test
doi:10.1371/journal.pone.0001523.t002
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PLoS ONE | www.plosone.org 4 February 2008 | Issue 2 | e1523the ROC curve (AUC) of 0.58. The AUC is a measure of the
discriminatory power of a test, ranging from 0.5 for no
discriminatory power to 1 for a perfect test [32]. We tested only
ten polymorphisms here, and there is reason to believe that the
predictive power of genetic information could be greater.
Increasing technological resources with decreasing costs are likely
to allow the inclusion, in models similar to that used in the present
study, of other genetic variants reproducibly associated to
functional consequences on coagulation factors, either newly
identified (i.e. the long-anticipated genetic modulators of Factor
VIII), or not included in this study (i.e. Factor XIII Val34Leu).
With larger data sets, it may also be possible to capture gene-gene
and gene-environmental factors.
Conclusions
Our datasupporttheideathat,whileindividualgeneticsusceptibility
variants are of limited clinical use, the combined information from a
number of these variants can permit the identification of groups of
people at high and low risk of developing a complex trait such as MI
[33,34]. The polygenic model used in this study, considering the
cumulative effect of hemostatic gene variants, was significantly
associated to some in vitro measurements of thrombin generation. In
the specific context of advanced CAD, similar approaches may be
useful as surrogate markers of the propensity to form blood clots
leading to MI. Further studies on larger samples are needed to
confirm this intriguing working-hypothesis, as well as to improve
predictive modelling.
Figure 2. OR for MI in groups stratified on the basis of number of unfavourable alleles. The intermediate group (from 3 to 7 unfavourable
prothrombotic alleles), representing the 85.3% of the whole population, is considered as reference group.
doi:10.1371/journal.pone.0001523.g002
Table 3. Correlations between number of procoagulant alleles
and different characteristics of thrombin generation activity.
......................................................................
Pearson
correlation
coefficient P
Number of procoagulant alleles–ETP (nM6min) 0.494 0.006
Number of procoagulant alleles–Lagtime (min) 0.187 0.332
Number of procoagulant alleles–Peak (nM) 0.244 0.203
Number of procoagulant alleles–Time to Peak (min) 0.230 0.230
Number of procoagulant alleles–Start Tail (min) 0.396 0.033
The analysis was performed in a subgroup of CAD patients (n=29) without
anticoagulant therapies and without signs of overt inflammation. Procoagulant
alleles were fibrinogen beta-chain -455 A, Prothrombin 20210 A, Factor V
Leiden, Factor V R2, Factor VII A1, Factor VII -402 A, PAI-1 -675 4G.
doi:10.1371/journal.pone.0001523.t003
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 4. Characteristics of thrombin activity generation curves
in groups stratified on the basis of number of procoagulant
alleles, with a threshold level at 5 alleles.
......................................................................
,5 alleles (n=19) $5 alleles (n=10) P
{
ETP (nM6min) 1,3416158 1,6616277 0.005
Lagtime (min) 6.4960.79 6.8961.33 0.326
Peak (nM) 191637 221643 0.058
Time to Peak (min) 10.0860.87 10.6461.59 0.224
Start Tail (min) 27.7662.84 30.2063.40 0.050
The analysis was performed in a subgroup of CAD patients (n=29) without
anticoagulant therapies and without signs of overt inflammation. Procoagulant
alleles were fibrinogen beta-chain -455 A, Prothrombin 20210 A, Factor V
Leiden, Factor V R2, Factor VII A1, Factor VII -402 A, PAI-1 -675 4G.
{: by t-test
doi:10.1371/journal.pone.0001523.t004
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Hemostatic Genes and MI Risk
PLoS ONE | www.plosone.org 5 February 2008 | Issue 2 | e1523MATERIALS AND METHODS
Study population
This study was performed within the framework of the Verona
Heart Project, a regional survey aimed to search for new risk
factors for CAD and MI in subjects with objective angiographic
documentation of their coronary vessels. Details about enrolment
criteria have been described in detail elsewhere [35,36]. A total of
804 subjects, for whom complete analyses of 10 polymorphisms of
genes involved in hemostatic pathways were available, were
included in the present study. Three-hundred fifteen subjects had
completely normal coronary arteries, being submitted to coronary
angiography for reasons other than CAD, mainly valvular heart
disease (CAD-free group). These controls were also required to
have neither history nor clinical or instrumental evidence of
atherosclerosis in vascular districts beyond the coronary bed. Four-
hundred eighty nine subjects had angiographically proven CAD
(the majority of them being candidates for coronary artery bypass
grafting) with objective documentation of presence/absence of MI.
The disease severity was determined by counting the number of
major epicardial coronary arteries (left anterior descending,
circumflex, and right) affected with $1 significant stenosis
($50%). According to the hypothesis to be tested, subjects with
non-advanced CAD (i.e. coronary stenosis ,50%) were not
included in the study. Cardiologists unaware that the patients were
to be included in the study assessed the angiograms. Patients were
classified into MI (n=307) and non-MI (n=182) subgroups on the
basis of a thorough review of medical records including history,
electrocardiogram, enzyme changes, and/or the typical sequelae
of MI on ventricular angiography.
All participants came from the same geographical area
(Northern Italy), with a similar socio-economic background. At
enrolment, a complete clinical history was collected, including the
assessment of cardiovascular risk factors such as obesity, smoking,
hypertension and diabetes. The study was approved by the Ethic
Committee of our Institution (Azienda Ospedaliera, Verona). A
written informed consent was obtained from all the participants
after a full explanation of the study.
Biochemical analysis
Samples of venous blood were drawn from each subject at
enrolment, before coronary angiography and after an overnight
fast. Serum lipids, as well as other CAD risk factors, including
high-sensitivity C-reactive protein (hs-CRP) were determined as
previously described [26].
Genetic analysis and nomenclature
Genomic DNA was extracted from whole blood samples by a
phenol-chloroform procedure using the Puregene kit (Gentra
Systems) according to the manufacturer’s protocol. The 10 genetic
polymorphisms, selected on the basis of prior evidence of potential
functionality in modulating the hemostatic pathway, are listed in
Table 1. Seven out of ten polymorphisms (fibrinogen beta-chain -
455G.A, Factor VII A1/A2, Factor V Leiden, Prothrombin 20210
G.A, PAI-1 -675 5G/4G, GP IIIa Leu33Pro, GP Ia/IIa alfa2 873
G.A) were examined by a previously described and validated
linear-array assays for candidate markers [37]. The accuracy of the
linear-array genotyping system as compared with standard geno-
typing approaches reported elsewhere [35,36] was evaluated and the
findings provide reassurance regarding the validity of the system
used, aspreviouslydescribed [38].The remaining three (Factor VII -
402 G.A, Factor V R2, P2RY12 H1/H2) were analyzed by
previously described, standard genotyping approaches [36,39,40].
Genotype interpretation for each polymorphism was performed
independentlyby twoinvestigatorsandveryfew samples(,1%)with
unclear result were re-genotyped.
Measurement of thrombin generation activity
This assay was performed in a subset of CAD patients on samples
drawn at enrolment, in order to evaluate a possible functional
counterpart of an increasing number of prothrombotic alleles in
terms of propensity to form blood clot. Plasma sample were
centrifuged at 23,000 g at 4uC for 1 hour before testing.
Calibrated automated thrombin activity measurement was
conducted according to Hemker et al. [41,42] in a microtiter
Figure 3. Comparison between the median thrombin generation activity curves in groups stratified on the basis of number of procoagulant
alleles, with a threshold level at 5 alleles.
doi:10.1371/journal.pone.0001523.g003
Hemostatic Genes and MI Risk
PLoS ONE | www.plosone.org 6 February 2008 | Issue 2 | e1523plate fluorometer (Fluoroskan Ascent, ThermoLabsystems, Hel-
sinki, Finland) using the Thrombinoscope software (Synapse BV,
Maastricht, The Netherlands). The assay was carried out at 37 uC
essentially as previously reported [43]. Coagulation was triggered
in platelet poor plasma by recalcification in the presence of 1 pM
recombinant human tissue factor and 4 mM phospholipids.
Thrombin generation was then evaluated overtime by exploiting
a specific fluorogenic substrate (Z-Gly-Gly-Arg-AMC). Thrombin
generation measurement was conducted in parallel in plasma
samples after the addition of a thrombin calibrator provided by the
manufacturer (Synapse BV). The software enables the estimate of
the following parameters: a) the Lag Time of thrombin generation,
b) the time to reach the maximum concentration of thrombin
(time to Peak), c) the maximum concentration of thrombin (Peak),
d) the total duration of thrombin generation activity (Start Tail),
and e) the total amount of thrombin activity assessed as the area
under the curve, i.e. the endogenous thrombin potential (ETP). All
experiments were carried out in duplicate.
Statistics
Calculations were performed mainly with SPSS 13.0 statistical
package (SPSS Inc., Chicago, IL). Distributions of continuous
variables in groups were expressed as means6standard deviation.
Logarithmic transformation was performed on skewed variables, for
whom geometric mean with 95% confidence interval (CI) are given.
Quantitative data were assessed using the Student’s t-test or by
ANOVA with Tukey’s post-hoc comparison of the means. Correla-
tions between quantitative variables were assessed using Pearson’s
correlation test. Qualitative data were analyzed with the x
2-test or the
Fisher exact-test when indicated. Hardy-Weinberg equilibrium was
t e s t e df o re a c hg e n o t y p ew i t h i ne a c hg r o u pb ym e a n so fx
2-test. A
value of P,0.05 was considered statistically significant.
Within each group examined, the frequencies of the genotypes
associatedwitheachofthepolymorphismswerecomparedbythex
2-
test, with the values predicted on the basis of the Hardy-Weinberg
equilibrium. To assess the extent to whichgene polymorphisms were
associated with MI, odds ratios with 95% CIs were estimated by
univariate logistic regression analysis. Adjustment for other variables
(i.e. number of affected vessels, age, sex, smoking, BMI, LDL- and
HDL-cholesterol) was performed by adding those covariates in a set
of multiple logistic-regression models.
The existence of gene-gene interactions was first explored by a
data mining technique similar to the Adaboost algorithm, and based
on classification and regression trees (CART): the gradient boosting
machine [44]. The statistical significance of the interactions found
with this method was then estimated by the likelihood ratio test
applied on two logistic models (with and without the interaction
terms).Afterobservingthatno significantinteractionwaspresent,we
focused on an additive model. On this basis, we attributed to each
patient a ‘‘prothrombotic score’’ (PS), reflecting the sum of 10
concomitant unfavourable prothrombotic alleles, theoretically
ranging from 0 (no prothrombotic allele present) to 20 (all the
prothrombotic alleles present). The association between the
prothrombotic score and MI was evaluated by x
2 for linear trend
analysis.Theprothromboticscorewasanalysed bylogisticregression
both as continuous variable and as categorised variable. Odds ratios
with 95% CIs were estimated by univariate logistic regression
analysis and then by multiple logistic regression with adjustment for
numberofaffected vessels,age,sex,smoking, BMI, LDL-and HDL-
cholesterol.The predictivity of ourmodelswas then evaluated by the
receiver-operating-characteristics (ROC) curve, estmating the area
under the curve (AUC).
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